Devansh Mehta
Publications by Devansh Mehta
2 publications found • Active 2026–2026
2026
2 publicationsAzoxymethane in Experimental Pharmacology: Molecular Mechanisms, Colorectal Carcinogenesis and Therapeutic Research Applications
Azoxymethane (AOM) is a synthetic alkylating procarcinogen widely employed in experimental pharmacology, toxicology and molecular oncology for investigating colorectal carcinogenesis. Although it does not possess an established therapeutic indication, its pharmacological and toxicological properties provide an important experimental framework for understanding chemical carcinogenesis and evaluating potential chemopreventive and anticancer interventions. Following metabolic activation, principally through cytochrome P450-dependent pathways, AOM generates methylating intermediates capable of producing DNA adducts, including O⁶-methylguanine. These alterations contribute to mutagenesis, epithelial dysregulation and colorectal tumour initiation. The combination of AOM with dextran sodium sulphate (DSS) has further established a reproducible experimental model of inflammation-associated colorectal cancer. This review examines the historical development, chemical characteristics, pharmacokinetic considerations, metabolic bioactivation, molecular mechanisms, cellular responses and toxicological profile of AOM. Particular attention is given to DNA damage, DNA repair mechanisms, KRAS and Wnt/β-catenin signalling, NF-κB activation, oxidative stress, NLRP3 inflammasome activity, apoptosis, autophagy and interactions with the intestinal microbiome. Contemporary applications in pharmacological research, including chemoprevention, natural-product evaluation, immunotherapy, microbiome-directed interventions and experimental drug screening, are discussed. Recent developments through 2026 highlight the importance of standardising AOM/DSS models and integrating microbiome, metabolomic and lipidomic investigations. The review concludes that AOM remains an important experimental carcinogenesis tool, provided its carcinogenic nature, model limitations and lack of direct therapeutic utility are recognised. Its principal translational value lies in facilitating the discovery and preclinical evaluation of safer and more effective colorectal cancer prevention and treatment strategies.
Molecular Mechanisms In the Pathogenesis of Diabetic Nephropathy: Historical Development, Intracellular Signalling Pathways, Molecular Targets and Contemporary Therapeutic Strategies
Diabetic nephropathy (DN), increasingly described within the broader clinical framework of diabetic kidney disease (DKD), represents a major microvascular complication of diabetes mellitus and a leading contributor to chronic kidney disease and end-stage kidney failure worldwide. Its pathogenesis involves complex interactions among chronic hyperglycaemia, haemodynamic abnormalities, oxidative stress, inflammatory mediators, mitochondrial dysfunction, endothelial injury, podocyte damage and progressive extracellular matrix accumulation. Historically, the understanding of DN has evolved from morphological descriptions of glomerulosclerosis to the identification of hyperfiltration, renin–angiotensin–aldosterone system activation and multiple intracellular signalling networks. This review examines the historical development and molecular basis of DN, emphasising advanced glycation end-products and receptor for advanced glycation end-products signalling, protein kinase C activation, polyol and hexosamine pathways, transforming growth factor-β/Smad signalling, nuclear factor-κB, mitogen-activated protein kinases, phosphatidylinositol-3-kinase/Akt/mTOR, AMP-activated protein kinase, Nrf2/Keap1, Wnt/β-catenin and NLRP3 inflammasome activation. Particular attention is given to podocyte dysfunction, glomerular endothelial abnormalities, tubular metabolic stress, epigenetic regulation and renal fibrosis. Contemporary therapeutic strategies, including renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists, are evaluated alongside landmark clinical trials and emerging molecular interventions. The review also discusses integrated treatment approaches, biomarker-based risk stratification and future therapeutic directions. Understanding the convergence of metabolic, haemodynamic and inflammatory pathways is essential for developing individualised, evidence-based interventions capable of delaying renal disease progression and improving long-term cardiorenal outcomes.
